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Alveolar macrophages are the most common cells in bronchoalveolar lavage fluid. The macrophages participate in 
the inflammatory response and defence of the airways by secretion of mediators and by phagocytizing foreign 
particles such as bacteria and viruses. P-Agonists and glucocorticosteroids are the most frequently used drugs in 
asthma. Alveolar macrophages have &adrenoceptors on their surface but the functional role of these receptors is 
unknown. Glucocorticosteroids interact with mediator release from macrophages. However, nothing is known about 
the effects of those drugs on the phagocytic capacity of alveolar macrophages. Therefore, the present study has 
investigated phagocytosis of alveolar macrophages from nine healthy volunteers after incubation with a &agonist, 
terbutaline (lo-‘, 10 ~ 6 and 10W4 M) and a glucocorticosteroid, budesonide (10 -9, 10e7 and lo- 5 M). 
Alveolar macrophages were incubated with FITC-labelled Escherichia coli, and the drugs and phagocytosis was 
assessed by flow cytometry. Phagocytosis was measured as the proportion of phagocytizing cells and mean 
fluorescence intensity (MFI). MFI was highly correlated with phagocytized E. coli per cell assessed by fluorescence 
microscopy (r = 0.996). 
The proportion of phagocytizing macrophages (control) was [median (25th-75th) percentiles] 46% (40-63) and 
29% (18-60), and MFI were 174 (154205) and 122 (90-271) in the terbutaline and budesonide experiments, 
respectively. Terbutaline did not affect the phagocytosis significantly, while budesonide decreased the phagocytic 
capacity (percent phagozytizing cells and MFI) in a dose-dependent manner (WO.01). At the highest budesonide 
concentration (10 ~ 5 M), phagocytosis was approximately half of the control situation. 
In conclusion, this in vitro study indicate that a glucocorticosteroid decreases phagocytosis in alveolar 
macrophages in a concentration that may be relevant in the airway lining fluid. Further investigations regarding the 
effect on other micro-organisms and in vivo effects are necessary to further elucidate these findings. 
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Introduction 
The alveolar macrophages are present in the respiratory 
tract, predominantly in the alveolar space, and contribute 
to the immunologic response of the airways by secretion of 
a number of cytokines and mediators which modulate the 
inflammatory reaction. Alveolar macrophages are capable 
of activating lymphocytes and eosinophils, and they partici- 
pate in the defence of the airways by presenting antigens 
and by phagocytosis of foreign particles such as bacteria, 
virus and airborne pollutants. 
&Adrenoceptors are present on most cell types in the 
airways; e.g. on smooth muscle cells where stimulation 
causes relaxation (l), on epithelial cells where stimulation 
causes increased ion transport and ciliary beating (2), and 
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on inflammatory cells such as mast cells, granulocytes 
and lymphocytes. P-Agonists reduce mediator release from 
mast cells (3) and eosinophils (4), and possibly from 
T-lymphocytes (5). Also, alveolar macrophages possess 
&receptors on their surface (6,7) but the functional role of 
these receptors is not defined. Glucocortiosteroids inhibit 
the synthesis and release of several cytokines, e.g. IL-l/?, 
TNF-a, IL-8 and GM-CSF in alveolar macrophage [for 
review, see (S)]. These effects may be of importance for the 
anti-asthmatic properties of the glucocorticoids, although 
the role of the macrophage in asthma is not fully under- 
stood. 
&-Agonists and glucocorticosteroids are frequently used 
in the treatment for asthma. Since both the P-agonists and 
the glucocorticosteroids have the potential to act on 
alveolar macrophages, it is of interest to investigate whether 
or not these drugs interact with phagocytosis, one of the 
most important macrophage functions. The aim of the 
present study was to study phagocytosis of opsonized 
FITC-labelled Escherichia coli after incubation with two 
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commonly used anti-asthmatic drugs, a &agonist, terbuta- 
line, and a glucocorticosteroid, budesonide, in a dose- 
response manner. Sotalol was used to investigate whether 
or not possible actions of p,-agonists were mediated 
through stimulation of the fi-adrenoceptor or by unspecified 
mechanisms. 
Materials and Methods 
SUBJECTS 
Nine healthy non-smoking volunteers (three men), mean 
age 30 (range 2045) years, participated in the study after 
giving their informed consent. All subjects denied present 
or former symptoms of allergic disease, asthma or other 
airway diseases. Spirometry and chest X-rays were normal 
in all subjects. The study was approved by the Ethics 
Committee of the Karolinska Hospital. 
BRONCHOALVEOLAR LAVAGE 
The bronchoscopy was performed through the nose with a 
flexible fibre-optic bronchoscope under local anaesthesia 
by 2% lignocaine (Xylocain, Astra, Siidertalje, Sweden), 
after premeditation with morphine-scopolamine. Broncho- 
alveolar lavage (BAL) was performed by wedging in a 
subsegmental middle lobe bronchus, and instilling five 
aliquots of 50 ml of sterile saline solution with a tempera 
ture of 37°C. After each instillation, the fluid was gently 
aspirated and collected in a siliconized bottle which was 
kept on ice. 
PHAGOCYTOSIS 
The cells were pelleted at 200 g for 10 min at 4°C. The pellet 
was resuspended in RPM1 1640 medium with 5% heat- 
inactivated FCS, 50pm ml- ’ gentamicin (GE) and 
100 pg ml - ’ penstrep (Biochrom KG, Seromed, Berlin, 
Germany). The total number of cells was determined by 
counting in a haemacytometer, and cell viability was deter- 
mined by the exclusion of Trypan blue. The median (25th- 
75th percentiles) total cell count per BAL were 22 x lo6 
cells (17-26) and viability was 90% (83-93). A total of 
2 x IO5 cells was seeded in 6 ml test tubes (Falcon, Becton 
Dickinson, New Jersey, U.S.A.) in triplicates for each drug 
and concentration, and kept on ice until drugs were added. 
During the drug incubations (terbutaline n=9, budesonide 
n=8), the cells were incubated in a shaking water bath at 
37°C. There were two groups of control cells for each drug, 
one kept on ice (baseline) and one incubated at 37°C. 
Phagocytosis was performed according to the 
PhagotestW (Pagotest@, Orpegen, Heidelberg, Germany). 
BAL fluid cells were incubated with fluoresceinisothio- 
cyanaten (FITC)-labelled E. coli opsonized with antibodies 
and complement of pooled sera and necessary reagents. 
BAL fluid cells (100 ~1) were pre-treated and incubated with 
drugs as mentioned above, and incubated in an ice-water 
bath for 15 min. Twenty microlitres of mixed pre-cooled 
E. coli bacteria (10’ ml - ‘, 0°C) was added to the test tubes 
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FIG. 1. Relationship between mean fluorescence intensity 
(MFI) and ingested E. coli per alveolar macrophage as 
assessed by fluorescence microscopy. 
and vortexed. Assay tubes were incubated for exactly 
10 min at 37°C in a shaking water bath, while a control 
remained in the ice-water bath. At the end of the incubation 
time, all samples were put in ice water at the same time and 
an ice-cold quenching solution (100~1) was added to each 
sample. Thereafter, 3 ml of ice-cold washing solution was 
added and subsequently the samples were centrifuged for 
5 min at 250 g, 4°C. The pellet was rewashed with washing 
solution and centrifuged again. Possible red blood cells 
were lysed and BAL cells were fixed with 3 ml prewarmed 
lysing solution for 20 min at room temperature and centri- 
fuged. The samples were then washed once with 3 ml of 
cold washing solution and centrifuged (5 min, 250 g, +4”C). 
One hundred microlitres of DNA staining solution was 
added, samples were incubated for 10 min at 0°C and 
measurement was performed within 30 min. 
Phagocytosis was assessed by flow cytometry (EPICS 
Profile II, Coulter Electronics Inc, Miami, FL, U.S.A.). The 
proportion of phagocytizing cells and mean fluorescence 
intensity (MFI) was assessed. In a control experiment, MFI 
was related to the number of E. coli per cell assessed by 
fluorescence microscopy. The coefficient of correlation 
between MFI and E. coli per cell was 0.996 (Pearsons 
coefficient of correlation, Fig. 1). 
DRUGS 
Terbutaline was dissolved in RPM1 medium. BAL fluid 
cells were incubated at 37°C for 90 min at three different 
concentrations (lo-‘, 10W6 and lop4 M). 
Budesonide was dissolved in ethanol (final concentration 
0.05%) and then in RPM1 1640. The cells were incubated 
for 20 h at 37°C at three different concentrations (10W9, 
10 ~ ’ and 10 - ’ M). The control cells were incubated with 
0.05% ethanol/RPM1 1640. 
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FIG. 2. Phagocytosis expressed as proportion of phagocytizing cells, mean fluorescence intensity (MFI) and number of 
phagocytized E. coli per cell in the control situation (37°C) and after incubation with terbutaline, sotalol and budesonide. 
There are no significant differences between baseline values for terbutaline and budesonide (Mann-Whitney U-test). 
Median values and 25&75th percentiles are presented. *P<O.OS, TP<O.Ol (Wilcoxon’s signed rank test) compared with 
control. 
Sotalol was dissolved in RPM1 1640 medium to a final 
concentration of lop5 M. BAL fluid cells were incubated 
with sotalol or a combination of sotalol and terbutaline 
(lop4 M). 
STATISTICS 
Results are presented as median values (25th-75th percen- 
tiles). A P value ~0.05 was considered significant. Statisti- 
cal comparisons are made by Friedmans test and Wilcoxon 
signed rank test when appropriate. Comparisons between 
control values were performed with the Mann-Whitney 
U-test. 
Results 
In the control situation, phagocytosis occurred in 46% 
(40-63) and 29% (18-60) of the macrophages, in the 
terbutaline and budesonide experiments, respectively. 
Terbutaline or sotalol did not influence the proportion of 
phagocytosing cells, while budesonide induced a significant 
decrease to 15% (10-54, P<O.Ol, Friedmans test, Fig. 2). 
Control values for MFI were 174 (154205) and 122 
(90-271) in the terbutaline and budesonide experiments, 
respectively. MFI was unaffected by the ,&-agonist and by 
b-blockade, while budesonide approximately halved the 
MFI to 68 (56-156) at the highest concentration (P<O.Ol, 
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Friedmans test, Fig. 2). The number of ingested E. coli 
in the control situation were 10.0 E. coli per cell (9.0-12.2) 
for terbutaline and 7.0 E. coli per cell (5.0-16.5) for 
budesonide. 
Budesonide decreased phagocytosis in a dose-dependent 
manner to half the control level, 3.5 E. co/i per cell (2.5-9.0) 
at the highest concentration (P<O.Ol, Friedmans test, 
Fig. 2). There were no significant differences between 
control values prior to terbutaline and budesonide incu- 
bation with regard to any of the measured parameters 
(Mann-Whitney U-test). 
Discussion 
The present study investigated the influence of terbutaline 
and budesonide on the phagocytic capacity of alveolar 
macrophages by assessing their ability to ingest FITC- 
labelled opsonized E. coli. Tertubaline had no influence on 
the phagocytic capacity up to a concentration of 10 - 4 M. 
Neither was there an effect of the P-blocker (sotalol) in this 
respect. Incubation with budesonide caused a significant 
dose-dependent decrease of the phagocytosis. The authors 
found an almost perfect correlation between MFI, express- 
ing the amount of phagocytized bacteria, and the number 
of E. co/i ingested per cell, as assessed by fluorescence 
microscopy. This result thus indicates that budesonide 
decreases phagocytosis in alveolar macrophages by decreas- 
ing the number of phagocyting cells as well as by decreas- 
ing the phagocytic capacity of the cells. The mechanism 
for this effect is not clear. It could be mediated by a 
glucocorticosteroid-specific mechanism or by non-specific, 
toxic mechanisms. The authors have, in their laboratory, 
clearly demonstrated that the viability of the alveolar 
macrophages remains at approximately 90% after the cells 
have been incubated with budesonide up to a concentration 
of 1O-4 M (data not shown). Thus, in the present study, 
incubation with budesonide did not affect the viability of 
the cells and it seems likely that the budesonide-induced 
inhibition of phagocytosis is mediated by a glucocortico- 
steroid-specific mechanism and not by toxic, non-specific 
mechanisms. 
Although phagocytosis is a basal immunologic defence 
mechanism of the airways, little is known about its impor- 
tance in healthy subjects and in different diseases. Studies of 
the influence of drugs on phagocytosis are sparse, and the 
authors are not aware of any studies in which the effect of 
glucocorticosteroids or /&-agonists have been investigated 
in this respect. In the present study, budesonide attenuated 
phagocytosis significantly at lo-’ M which is a concen- 
tration that could be expected to occur in the airways during 
regular treatment of asthma (9). The highest concen- 
tration used (10 ~ ’ M) is probably too high to be clinically 
relevant (9). Thus, glucocorticosteroids influence phago- 
cytic capacity in vitro in concentrations that may be relevant 
in the clinical, in vivo situation, This study was performed 
on FITC-labelled opsonized E. coli and it is not clear to 
which extent these results can be generalized. Further inves- 
tigations with other agents and species, and investigations in 
the in vivo situation, may therefore be of interest. 
This study indicates that &adrenoceptors are not 
coupled to phagocytic capacity of alveolar macrophages, as 
incubation with a &-agonist (terbutaline) or a P-blocker 
(sotalol) did not affect phagocytosis. The concentrations 
used are of the magnitude that has been claimed to occur in 
the airway lining fluid (10). Alveolar macrophages produce 
oxygen metabolites in association with phagocytosis (1 l), 
and can be activated to produce superoxide anions by many 
agents, e.g. zymosan (12). Capelli et ul. found no effect of 
salbutamol or formoterol on superoxide anion production 
in patients with chronic bronchitis, after incubation of 
unstimulated alveolar macrophages (13). In the same study, 
however, formoterol decreased superoxide anion produc- 
tion following stimulation of alveolar macrophages with 
zymosan. 
Inhaled glucocorticosteroids are frequently used in the 
treatment of asthma, and are also used in the treatment of 
chronic obstructive pulmonary disease (COPD). Phago- 
cytosis of foreign particles are of importance in the defence 
against infections. In COPD patients, who are often 
infected and chronically colonized by bacteria, an attenu- 
ated capacity to phagocytize bacteria could be deleterious. 
The present in vitro results indicate that budesonide may be 
able to influence this capacity. Although a decrease to 
approximately half of the phagocytic capacity after incu- 
bation with budesonide was found, there is still a remaining 
phagocytic capacity even at the highest dose. Thus, despite 
high concentrations of budesonide, the alveolar macro- 
phages still have, although depressed, a capacity to ingest 
bacteria. It is not clear whether the depression of phago- 
cytosis found in this in vitro study is sufficient to influence 
the defence mechanisms in the airways during treatment 
with inhaled glucocorticosteroid. Although the external 
validity and clinical relevance of these findings are not clear, 
the results may indicate an unfavourable effect of one of the 
most frequently used anti-asthmatic therapies. Further 
studies have to evaluate whether or not these findings are of 
clinical importance. 
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